Patient Group Direction for the Supply of bupropion (Zyban™)

The above named Patient Group Direction (PGD) has been written by:			
Position of Signatory	**Name**	**Signature**	**Date**
Doctor	Dr ~~Adrian~~ Berry PP DR SUBHA THIYAGESH		2-10-17
Pharmacist	Kate Dewhirst		18/9/17.
Pharmacist	Sarah Hudson		08/09/17

The above named Patient Group Direction (PGD) has been approved and authorised for use by:			
Position of Signatory	Name	Signature	Date
DEPUTY Medical Director	Dr ~~Adrian~~ Berry DR SUBHA THIYAGESH	PP	2-10-17

Characteristics of staff to whom the Patient Group Direction applies.

Qualifications required	Pharmacist registered with General Pharmaceutical Council, working within and for a pharmacy with an agreement with Yorkshire Smokefree to provide bupropion under PGD. It is the responsibility of the individual pharmacist to ensure that they and their staff are competent in all aspects of supply of bupropion. This PGD will only apply whilst the pharmacist is employed or contracted/working at the time in an accredited Pharmacy within Sheffield
Additional requirements	Accredited pharmacies will have a suitable private consultation room / area which are available for all client consultations.

	The practitioner should be aware of any change to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with continued professional development and to work within the limitations of individual scope of practice.

Date of implementation of this PGD - 1st October 2017
Date of review of this PGD/Date expires - 30th September 2020

Name	Bupropion Hydrochloride (Zyban™)
Legal Status	Prescription Only Medicine
Type	Modified release tablet

Description:	**Bupropion Hydrochloride 150mg MR Tablet**
Dosage:	**Adult** Initially 150 mg daily for 6 days, then 150 mg twice daily (max. per dose 150 mg), minimum 8 hours between doses; period of treatment 7–9 weeks, start treatment 1–2 weeks before target stop date, discontinue if abstinence not achieved at 7 weeks, consider maximum 150 mg daily in patients with risk factors for seizures; maximum 300 mg per day. **Elderly** 150 mg daily for 7–9 weeks, start treatment 1–2 weeks before target stop date, discontinue if abstinence not achieved at 7 weeks; maximum 150 mg per day.
Route to Administration:	Oral
Total dose, duration of treatment, total treatment quantity:	See above
Storage of Medication:	Do not store above 25°C. Store in the original package.

Criteria for administration	• Over 18 years of age • Patient wanting to stop smoking • Patient receiving motivational support from Yorkshire Smokefree (Sheffield)

Groups excluded from treatment (Contraindications):	• Acute alcohol withdrawal • Acute benzodiazepine withdrawal • Bi-polar disorder • Central Nervous system Tumour • Eating disorder • History of seizures • Severe hepatic cirrhosis
Precautions	• Alcohol abuse • Diabetes • Elderly • History of Head trauma • Pre-disposition to seizures (see notes above and benefits must outweigh risk)
Action if patient excluded:	Refer to seek advice from Medical Practitioner or refer back to Yorkshire Smokefree (Sheffield)

Action if patient declines treatment:	Consider other treatment options or refer to appropriate Medical Practitioner or refer back to Yorkshire Smokefree (Sheffield)
Potential mild adverse reactions	Agitation; anxiety; depression; dizziness; dry mouth; fever; gastro-intestinal disturbances; headache; impaired concentration; insomnia (reduced by avoiding dose at bedtime); pruritus; rash; sweating; taste disturbance; tremor
Severe adverse reaction	Anorexia; asthenia; chest pain; confusion; flushing; hypertension; tachycardia; tinnitus; visual disturbances abnormal dreams; ataxia; blood-glucose changes; depersonalisation; dystonia; exacerbation of psoriasis; hallucinations; hepatitis; hostility; impaired memory; incoordination; irritability; jaundice; palpitation; paraesthesia; postural hypotension; seizures; Stevens-Johnson syndrome; twitching; urinary frequency; urinary retention; vasodilatation
Procedure for reporting adverse drug reactions:	Inform Yorkshire Smokefree (Sheffield) Yellow card scheme
Written and verbal advice for patient/carer	All patients should be given the Patient information leaflet in the box (PIL) Specific advice should be given with regards to symptoms of depression and anxiety associated with withdrawal from nictotine
Record of supply/administration	Complete voucher supplied by patient and record on PMR and Quitmanager
Follow-up	Patient will be followed up via Yorkshire Smokefree (Sheffield)
References	Current Edition BNF Specific Product Characteristics Zyban update 4th May 2017

Management of Patient Group Direction

This Patient Group Direction is to be read, agreed to and signed by all registered Pharmacists it applies to.

I confirm that I have read and understood the content of this patient group direction and that I am willing and competent to work under it within my professional code of conduct.

Name of Pharmacist	Signature of Pharmacist	Date Signed